Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's NDA And BLA Approvals: Kymriah, Vabomere, Cyltezo

Executive Summary

Original new drugs and biologics recently approved by US FDA.

You may also be interested in...



Top US FDA Official Says New 'Playbook' Needed For CMC Reviews Of Gene Therapy Products

CBER director says lack of a clear regulatory structure is holding back the development and acceleration of gene therapy products, while industry says regulations should be flexible to keep up with changing technology for these products.

Proceeds From Chagas Treatment Priority Review Voucher Will Help Ensure Access

US FDA approved its first treatment for the tropical disease and awarded a priority review voucher that will be sold as per agreement between development partners.

Novartis CAR-T Therapy's Swift Approval Aided By REMS And New US FDA Review Model

Risk Evaluation and Mitigation Strategy for Kymriah requires the acute lymphoblastic leukemia treatment be administered by certified centers, while a postmarketing study will assess safety over 15 years. FDA's early approval reflects efforts by the biologics center and new cross-cutting Oncology Center for Excellence to implement a more collaborative review model.

Related Content

Topics

UsernamePublicRestriction

Register

PS121423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel